To determine the contribution of the major body fat depots to systemic free fatty acid (FFA) 
Introduction
Upper body obesity, as assessed by waist-hip circumference ratio (WHR),' is a major risk factor for hypertension, glucose intolerance, and hypertriglyceridemia (1) (2) (3) . Conversely, individuals with lower body obesity may have comparable amounts ofbody fat but remain relatively free ofthe metabolic consequences of obesity. Although the mechanism(s) by which upper body obesity results in adverse health effects is unknown, it has been suggested that increased free fatty acid (FFA) availability, resulting from increased effective adipose tissue lipolysis, might be directly responsible for some of the observed abnormalities (4-6).
We have previously reported that upper body obesity in women is associated with increased FFA availability relative to lean tissue needs compared with nonobese and lower body obese women (7) . In order for lower body obese women to maintain appropriate FFA availability despite increased fat mass, there must be down-regulation of lipolysis to prevent FFA release from increasing in proportion to body fat. Conversely, this process must fail to some extent in upper body obese women. Whether this failure is a regional, versus generalized, phenomena is unknown. The former hypothesis is supported by the finding ofadipose tissue lipolytic heterogeneity in vitro (8, 9) and in vivo (10, 11) .
Unfortunately, there is no information regarding the potential contributions ofthe major body fat depots to systemic FFA availability in vivo in humans. To address these issues we have measured FFA release from leg, non-leg, and splanchnic beds in nonobese women and obese women with differing body fat distributions. Our findings localize upper body subcutaneous fat as a major site of excess FFA release in healthy, premenopausal upper body obese women.
Methods
Subjects. Informed written consent was obtained from 14 healthy, moderately obese (body mass index [BMI] 29-36 kg/m2) premenopausal women and six nonobese (BMI 20-24 kg/m2) premenopausal women. Obese subjects were selected such that six were defined as lower body obese (WHR < 0.76) and eight subjects were selected as upper body obese (WHR > 0.85). Waist circumferences were measured at the natural (smallest) waist with the subject in the supine position, and hip measurements were made at the maximum circumference with the subject standing with feet together. All women were in good health and taking no medications known to affect FFA metabolism. The volunteers had maintained a stable weight for > 2 mo before the studies and were instructed to consume a minimum of200 g ofcarbohydrate daily for at least 2 wk before the studies. A summary of the subjects' clinical characteristics is provided in Table I . Because of the demographics of our region, all of the women were Caucasian.
Materials. [l1-'4C]palmitate (Research Products International
Corp., Mount Prospect, IL) was prepared for intravenous infusion as previously described (12) . Indocyanine green (Cardio-Green, Becton, Dickinson & Co., Cockeysville, MD) was prepared as a 1.9% human serum albumin solution in 0.40% sodium chloride.
Assays. Plasma palmitate concentration and specific activity were determined using high-performance liquid chromatography (HPLC) (13, 14) . Plasma insulin concentrations were measured by radioimmunoassay (15) . Plasma indocyanine green concentrations were measured by a modification of a previously published HPLC technique (16) . Briefly, 0.5 ml ofplasma was mixed with 50 ,l ofmethanolic diazepam (1 mg in 100 ml) as the internal standard, and 0.5 ml ofacetonitrile was added to precipitate plasma proteins. This solution was vortexed and centrifuged at 1,700 g for 1 min. The supernatant was injected onto an HPLC column within 40 min ofsample preparation. Chromatography was performed on a C18 reverse-phase I0-1m column and eluted with cally treated standards. Analysis ofplasma samples was performed immediately after each study since degradation ofindocyanine green after overnight freezing was found to occur. Subjects having hepatic vein indocyanine green concentrations of > 0.5 mg/liter were excluded from the splanchnic portion of the study because these samples were considered to have been contaminated with inferior vena caval blood. Protocol. Lean body mass (LBM) was measured with tritiated water space and/or body potassium counting (17) before the study. Total body and regional fat content were measured using dual-energy x-ray absorptiometry (model DPX, Lunar Radiation Corp., Madison, WI) (18) . Subjects were scanned using the 20-min whole-body scan time, and region of interest analysis was performed using software version 3.1 (18) . Calibration of the model DPX was confirmed every 1-2 wk with a series of four phantoms composed of a range (4-61% fat) of known quantities offat and lean (19) (20) was estimated by using the region ofinterest program to quantitate the amount of fat between the pubic rami and the diaphragm. Abdominal skinfold thicknesses were measured in four separate areas ofthe abdomen using skinfold calipers.
Each subject was admitted to the Mayo Clinic General Clinical Research Center the evening before the study where they received a standard evening meal. The following morning, after an overnight fast, an 18-gauge infusion catheter was placed in a forearm vein, and patency was maintained with a 0.45% NaCl infusion at 20 ml/h. Blood was sampled before starting the isotope and indocyanine green infusions to be used for background palmitate specific activity and for construction of the indocyanine green calibration curve.
The Calculations. Plasma palmitate concentration and specific activity were constant over the sampling intervals; therefore, steady-state equations were used to calculate palmitate flux (12) using the mean palmitate specific activity for each subject. Hepatic plasma flow was calculated using the Fick principle and plasma indocyanine green clearance as previously described (21) . Leg plasma flow was calculated according to the method of Jordfelt and Wahren (22) . Regional (splanchnic and leg) palmitate uptake and release were calculated using previously published equations (11) .
The following values were calculated using the palmitate kinetic data combined with body composition analysis: To examine the potential contribution of visceral fat to total abdominal fat in these subjects we estimated subcutaneous and visceral fat mass as follows: (a) abdominal circumference was used to calculate abdominal radius, (b) abdominal radius -mean subcutaneous skinfold thickness = radius of intra-abdominal tissues; (c) total abdominal area -intra-abdominal area = subcutaneous adipose tissue area; (d) Subcutane Table I . Leg fat content refers to the leg from which palmitate kinetic data were obtained.
* P < 0.001 cf. other groups.
Results
Subject characteristics (Table I Bodyfat content (Table II) . Total body fat mass was similar in both groups of obese women and greater (P < 0.001) than that present in nonobese women. As expected, abdominal fat content was greater in upper body obese than lower body obese women, whereas leg fat mass was greater in lower body obese than upper body obese women. Although these differences were not statistically significant, the contribution of leg fat to total body fat in lower body obese and nonobese women (41±1% vs. 43±2%, respectively, P = NS) was greater (P < 0.05) than in upper body obese women (36±1%).
Using the calculations outlined in the Methods section, abdominal subcutaneous fat was estimated to be 9.7±0.9, 7.4±0.4, and 3.1±0.5 kg in upper body obese, lower body obese, and nonobese women, respectively (each value significantly different from each other value, P < 0.05). Thus, visceral fat was calculated to be 3.9±0.6, 4.4±1.0, and 1.8±0.5 kg in upper body obese, lower body obese, and nonobese women. The value for nonobese women is less (P < 0.05) than both groups of obese women, whose values were not statistically different.
Palmitate kinetics (Table III 3.7±0.3 ,umol * kg far' * min-', P < 0.01). Upper body fat palmitate release was less (P < 0.01) in lower body obese women than either nonobese or upper body obese women, whose values were not significantly different (Fig. 2) . Splanchnic plasma flow was 1,097±159, 885±59, and 991 ± 118 ml/min in upper body obese, lower body obese, and nonobese women. None of the differences were statistically significant. Net splanchnic palmitate release was similar in all three groups of women and represented 20±5%, 23±6%, and 32±5% of upper body palmitate release in upper body obese, lower body obese, and nonobese women, respectively (P = NS between groups).
Discussion
These experiments were designed to examine whether lower body (leg) and upper body (non-leg) adipose tissue release FFA at different rates in humans and to determine whether the increased FFA flux present in upper body obesity is due to a regional, versus generalized, enhancement oflipolysis. By combining isotope dilution methodology for FFA turnover, limb and splanchnic balance techniques, together with regional and total body tissue composition analysis, we were able to determine that leg fat is less lipolytically active than upper body fat. In addition, we have confirmed our previous observation that upper body obesity is associated with increased FFA flux relative to lean tissue needs (7), and localized upper body subcutaneous fat as the site ofexcess FFA release in healthy, premenopausal upper body obese women.
It is now apparent that the heterogeneity of body fat distribution in obesity extends beyond the simple upper body vs. lower body model. Increased visceral fat is a better predictor of hypertension, hyperlipidemia, and non-insulin-dependent diabetes than upper body subcutaneous fat (24, 25) . The selection of healthy, upper body obese women, taking no medications, might exclude viscerally obese women from these studies. Although our ability to exactly quantitate abdominal subcutaneous and visceral fat was somewhat limited by the methodology available to us at the time of these studies, the upper body obese volunteers would likely be characterized as abdominal subcutaneous obesity. It is unknown whether visceral obesity would result in similar abnormalities of FFA metabolism.
Quantitation of our subjects' intra-and extra-abdominal fat with computed tomography (24) (25) (26) or magnetic resonance imaging (27) would have been preferable, however, the combination of dual-energy x-ray absorptiometry and anthropomorphic measurements provided data consistent with previous studies. Our estimates ofabdominal subcutaneous area in nonobese women (106±15 cm2) is consistent with that reported by Baumgardner et al. (26) for midabdominal subcutaneous area measured by computed tomographic scanning. Mean, midabdominal visceral adipose tissue area (intra-abdominal plus retroperitoneal) in these same women (26) It is important to note that our measurement ofsplanchnic palmitate release is not a measure of splanchnic lipolysis. Note that splanchnic palmitate uptake was approximately threefold greater than release. Free fatty acid uptake occurs in both intestine and liver (28) , whereas release ofFFA into the portal circulation occurs from omental and mesenteric adipose tissue. Because the proportion of nonhepatic splanchnic FFA uptake in humans is unknown, splanchnic lipolysis cannot be predicted accurately. If all FFA uptake occurred in nonhepatic tissues, splanchnic FFA release would equal splanchnic lipolysis (a minimum estimate). If all splanchnic FFA uptake occurred in the liver, then the fractional uptake ofFFA newly released into the portal circulation should equal fractional uptake ofsystemically delivered FFA (-50%). The maximum estimate of splanchnic lipolysis from these studies would then be approximately double splanchnic release (-30-50 umol/min). Visceral adipose tissue palmitate release might range from 4 to 22 ,umol * kg far' -min-'. It does not appear to be possible to estimate more accurately visceral adipose tissue lipolysis in humans at the present time without access to the portal vein.
The most significant observation of the present studies is the difference in upper body fat lipolytic activity between lower body and upper body obese women. This difference is emphasized by the similarity ofleg fat FFA release in these two groups of obese women. Despite increased upper body fat mass in lower body obese women, upper body FFA release was not elevated, thus preventing excess availability relative to lean tissue needs. It appears that as upper body fat mass increases in subcutaneous upper body obesity there is a failure to decrease lipolysis (e.g., FFA release per kilogram offat remains identical to nonobese women). Thus, FFA flux in subcutaneous upper body obesity may increase in proportion to the increase in upper body, but not leg, fat. Despite the increased leg fat mass in both lower body obese and upper body obese women, leg palmitate release did not increase. This suggests that leg adipose tissue in these two types of obesity is down regulated with regard to lipolysis.
How upper body fat is down regulated in lower body obese women, and why this fails to occur in subcutaneous upper body obesity is unknown. Kissebah and colleagues (29) have demonstrated that abdominal subcutaneous adipocyte size is dramatically increased in upper body obese women compared with lower body obese and nonobese women, whereas thigh adipocyte size remains similar. Perhaps the increased size of upper body subcutaneous adipocytes in upper body obesity, with the resulting increase in unstimulated lipolysis (29) , is permissive in the disregulation of upper body fat lipolysis. An understanding of the mechanism by which lower body obese women increase upper body fat mass by increasing fat cell number, whereas upper body obese women increase upper body fat cell size, might guide investigations into potential etiologic differences in these two types of obesity.
In addition to the potential effects ofexcess FFA to result in hypertriglyceridemia (6) and insulin resistance with regards to glucose utilization (4, 5) , it has recently been demonstrated that FFA may affect hepatic insulin metabolism (30, 31) . The exposure of hepatocytes to physiologic increases in FFA concentration reduced insulin clearance (30, 31) . It is interesting to note that reduced hepatic insulin clearance has been found in upper body obese women (32) .
In summary, the present in vivo studies are the first to show quantitative differences in FFA release from upper body versus lower body fat in overnight postabsorptive humans. In addition, we found that as leg fat mass increases in upper body and lower body obesity, no increase in leg FFA release occurs. In contrast, upper body FFA release increases proportionately with increased fat mass in subcutaneous upper body obesity, but not in lower body obese women. These observations not only localize the increased FFA released to upper body subcutaneous fat in upper body obesity, but suggest that a quantitation of fat in different body regions may lack predictive value for some of the metabolic consequences of obesity.
